Campbell Newman Asset Management 13F: New $1.9M Stake in AMRX
Key Points
- Campbell Newman Asset Management acquired a new holding of 92,293 shares in Amneal Pharmaceuticals, Inc. valued at approximately $1.86 million in a filing on October 22, 2026.
- Other large fund managers adjusted their stakes, including Neuberger Berman Group, LLC growing its position by 204,743 shares to end with 3,887,179 shares worth about $79.61 million.
- The drug maker recently traded around $20.48 as of October 23, 2026, sitting near its 52-week high of $21.18.
Get Amneal Pharmaceuticals text alerts
We text you when insiders, Congress, analysts or big funds move on $AMRX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Amneal Pharmaceuticals, Inc. alert may contain errors. Disclosures
Campbell Newman Asset Management opened a new position in Amneal Pharmaceuticals, Inc. [AMRX], acquiring 92,293 shares valued at about $1.86 million. The investment came to light in a Form 13F filing submitted to the Securities and Exchange Commission on October 22, 2026.
AMRX
Amneal Pharmaceuticals, Inc.
What Changed in Campbell Newman Asset Management's Amneal Pharmaceuticals, Inc. Position
The fund established a fresh stake in the drug maker during the quarter, buying 92,293 shares from scratch. No prior shares were held in this name by the firm.
Other Institutional Activity in Amneal Pharmaceuticals, Inc.
TPG GP A, LLC kept its holdings steady at 12,328,767 shares worth roughly $252.49 million. Rubric Capital Management LP reduced its holdings by 868,635 shares, ending with 10,168,660 shares valued at about $208.25 million, which marked a 7.9% decrease. Neuberger Berman Group, LLC grew its holdings by 204,743 shares, ending with 3,887,179 shares worth about $79.61 million, representing a 5.6% increase.
Amneal Pharmaceuticals, Inc. Stock Up 1.4%
The stock recently traded around $20.48 as of October 23, 2026, sitting just 3.3% below its 52-week high of $21.18. Shares have climbed significantly over the past year, trading well above their 52-week low of $9.99 and moving higher than both their 50-day moving average of $18.75 and their 200-day moving average of $15.50.
Recent Earnings
Amneal generated trailing twelve-month revenues of $3.12 billion alongside trailing earnings of $0.49 per share. The company posted a year-over-year revenue growth rate of 9.9% with a net profit margin of 5.0%. Its next earnings report is slated for November 3, 2026.
Insider Buying and Selling at Amneal Pharmaceuticals, Inc.
Deborah M Autor, Director, sold 34,819 shares at an average price of $12.94 on May 11, 2026, for a total value of $450,558. Nikita Shah, Officer, sold 146,403 shares at an average price of $17.51 on August 12, 2026, for a total value of $2.56 million. Jason B. Daly, Officer, disposed of 216,613 shares on August 12, 2026, valued at $3.77 million. John J. Kiely, Director, sold 50,000 shares at an average price of $17.64 on August 13, 2026, for a total value of $882,000.
Analysts Set New Price Targets
UBS maintained a Buy rating and raised its target from $23.00 to $25.00 on August 3, 2026. Leerink Partners initiated an Outperform rating with a $23.00 target on September 9, 2026. Barclays maintained an Overweight rating and lifted its target from $16.00 to $20.00 on September 17, 2026. Oppenheimer initiated an Outperform rating with a $27.00 target on September 23, 2026. JP Morgan maintained an Overweight rating and raised its price target from $22.00 to $24.00 on October 22, 2026. Wall Street maintains a consensus strong buy rating on the shares with a mean price target of $23.00 across 7 analyst opinions.
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. is a global healthcare business that develops, manufactures, and distributes generic, injectable, biosimilar, and specialty branded pharmaceutical products. The firm operates across multiple international markets through its Affordable Medicines, Specialty, and AvKARE business segments.
Bottom Line
Investors tracking the stock will look toward the upcoming earnings release on November 3, 2026, for fresh updates on financial health. Institutional filings show ongoing adjustments by professional money managers as the share price trades near upper boundaries.
Related Filing Alerts
Source: Campbell Newman Asset Management's 13F filing on $AMRX (Oct 22, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts